Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 4.39
HSKA's Cash-to-Debt is ranked higher than
56% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. HSKA: 4.39 )
Ranked among companies with meaningful Cash-to-Debt only.
HSKA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.77 Max: No Debt
Current: 4.39
Equity-to-Asset 0.64
HSKA's Equity-to-Asset is ranked higher than
58% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. HSKA: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
HSKA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: 0.78
Current: 0.64
0.02
0.78
Interest Coverage 76.74
HSKA's Interest Coverage is ranked higher than
54% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. HSKA: 76.74 )
Ranked among companies with meaningful Interest Coverage only.
HSKA' s Interest Coverage Range Over the Past 10 Years
Min: 1.89  Med: 12.04 Max: 76.74
Current: 76.74
1.89
76.74
Piotroski F-Score: 5
Altman Z-Score: 7.59
Beneish M-Score: -2.06
WACC vs ROIC
5.84%
12.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.29
HSKA's Operating Margin % is ranked higher than
73% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. HSKA: 11.29 )
Ranked among companies with meaningful Operating Margin % only.
HSKA' s Operating Margin % Range Over the Past 10 Years
Min: -1.83  Med: 3.67 Max: 11.29
Current: 11.29
-1.83
11.29
Net Margin % 7.55
HSKA's Net Margin % is ranked higher than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. HSKA: 7.55 )
Ranked among companies with meaningful Net Margin % only.
HSKA' s Net Margin % Range Over the Past 10 Years
Min: -1.53  Med: 2.67 Max: 42.28
Current: 7.55
-1.53
42.28
ROE % 13.22
HSKA's ROE % is ranked higher than
76% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. HSKA: 13.22 )
Ranked among companies with meaningful ROE % only.
HSKA' s ROE % Range Over the Past 10 Years
Min: -2.49  Med: 4.84 Max: 140.27
Current: 13.22
-2.49
140.27
ROA % 7.97
HSKA's ROA % is ranked higher than
80% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. HSKA: 7.97 )
Ranked among companies with meaningful ROA % only.
HSKA' s ROA % Range Over the Past 10 Years
Min: -1.49  Med: 3.03 Max: 61.02
Current: 7.97
-1.49
61.02
ROC (Joel Greenblatt) % 38.24
HSKA's ROC (Joel Greenblatt) % is ranked higher than
77% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. HSKA: 38.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HSKA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.69  Med: 14.71 Max: 38.24
Current: 38.24
-5.69
38.24
3-Year Revenue Growth Rate 3.70
HSKA's 3-Year Revenue Growth Rate is ranked higher than
50% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. HSKA: 3.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HSKA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 10.4
Current: 3.7
-16.9
10.4
3-Year EBITDA Growth Rate 37.30
HSKA's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. HSKA: 37.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HSKA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: -21.7 Max: 37.3
Current: 37.3
-63.9
37.3
3-Year EPS without NRI Growth Rate 49.80
HSKA's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. HSKA: 49.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HSKA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -35.5 Max: 49.8
Current: 49.8
0
49.8
GuruFocus has detected 3 Warning Signs with Heska Corp $HSKA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSKA's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HSKA Guru Trades in Q1 2016

Mario Gabelli 50,200 sh (unchged)
Jim Simons 180,781 sh (-21.94%)
» More
Q2 2016

HSKA Guru Trades in Q2 2016

Mario Gabelli 50,200 sh (unchged)
Jim Simons 121,680 sh (-32.69%)
» More
Q3 2016

HSKA Guru Trades in Q3 2016

Chuck Royce 37,000 sh (New)
Mario Gabelli 48,200 sh (-3.98%)
Jim Simons 38,180 sh (-68.62%)
» More
Q4 2016

HSKA Guru Trades in Q4 2016

Chuck Royce 44,000 sh (+18.92%)
Jim Simons Sold Out
Mario Gabelli 45,700 sh (-5.19%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541940    SIC: 742
Compare:NAS:VIVO, NAS:NTRA, NAS:NEO, NAS:NRCIA, NAS:QDEL, NAS:BEAT, NYSE:ARA, NYSE:NVTA, NAS:NVDQ, NAS:LNTH, NAS:SRDX, NYSE:ENZ, NAS:ONVO, NAS:OXFD, NAS:FMI, NAS:RDNT, OTCPK:CBIS, AMEX:SENS, NAS:FLGT, NAS:QTNT » details
Traded in other countries:HSKN.Germany,
Heska Corp is engaged in developing, manufacturing, marketing, selling and supporting veterinary products. The Company's core focus is on the canine and feline companion animal health markets.

Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 uL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.

Ratios

vs
industry
vs
history
PE Ratio 64.80
HSKA's PE Ratio is ranked lower than
90% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. HSKA: 64.80 )
Ranked among companies with meaningful PE Ratio only.
HSKA' s PE Ratio Range Over the Past 10 Years
Min: 0.49  Med: 34.49 Max: 604
Current: 64.8
0.49
604
Forward PE Ratio 51.81
HSKA's Forward PE Ratio is ranked lower than
91% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. HSKA: 51.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 64.80
HSKA's PE Ratio without NRI is ranked lower than
89% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. HSKA: 64.80 )
Ranked among companies with meaningful PE Ratio without NRI only.
HSKA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.49  Med: 34.49 Max: 604
Current: 64.8
0.49
604
PB Ratio 6.74
HSKA's PB Ratio is ranked lower than
77% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. HSKA: 6.74 )
Ranked among companies with meaningful PB Ratio only.
HSKA' s PB Ratio Range Over the Past 10 Years
Min: 0.22  Med: 1.27 Max: 25.79
Current: 6.74
0.22
25.79
PS Ratio 4.89
HSKA's PS Ratio is ranked lower than
62% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. HSKA: 4.89 )
Ranked among companies with meaningful PS Ratio only.
HSKA' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.77 Max: 5.08
Current: 4.89
0.12
5.08
Price-to-Free-Cash-Flow 586.97
HSKA's Price-to-Free-Cash-Flow is ranked lower than
97% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. HSKA: 586.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HSKA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.43  Med: 18.66 Max: 611.08
Current: 586.97
2.43
611.08
Price-to-Operating-Cash-Flow 118.40
HSKA's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. HSKA: 118.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HSKA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.36  Med: 24.24 Max: 280.59
Current: 118.4
2.36
280.59
EV-to-EBIT 41.08
HSKA's EV-to-EBIT is ranked lower than
86% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. HSKA: 41.08 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s EV-to-EBIT Range Over the Past 10 Years
Min: -111.6  Med: 22.2 Max: 172
Current: 41.08
-111.6
172
EV-to-EBITDA 31.21
HSKA's EV-to-EBITDA is ranked lower than
83% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. HSKA: 31.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSKA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43  Med: 12.6 Max: 58.4
Current: 31.21
-43
58.4
PEG Ratio 3.95
HSKA's PEG Ratio is ranked lower than
61% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. HSKA: 3.95 )
Ranked among companies with meaningful PEG Ratio only.
HSKA' s PEG Ratio Range Over the Past 10 Years
Min: 3.95  Med: 51.7 Max: 65.79
Current: 3.95
3.95
65.79
Shiller PE Ratio 77.08
HSKA's Shiller PE Ratio is ranked lower than
79% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. HSKA: 77.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
HSKA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.39  Med: 21.22 Max: 339.33
Current: 77.08
7.39
339.33
Current Ratio 2.76
HSKA's Current Ratio is ranked higher than
53% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. HSKA: 2.76 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.95 Max: 5.19
Current: 2.76
1.03
5.19
Quick Ratio 1.62
HSKA's Quick Ratio is ranked lower than
64% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. HSKA: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.1 Max: 4.4
Current: 1.62
0.56
4.4
Days Inventory 93.84
HSKA's Days Inventory is ranked lower than
53% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. HSKA: 93.84 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s Days Inventory Range Over the Past 10 Years
Min: 82.09  Med: 106.38 Max: 109.49
Current: 93.84
82.09
109.49
Days Sales Outstanding 48.49
HSKA's Days Sales Outstanding is ranked higher than
72% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. HSKA: 48.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.35  Med: 49.25 Max: 56.31
Current: 48.49
41.35
56.31
Days Payable 31.33
HSKA's Days Payable is ranked lower than
72% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. HSKA: 31.33 )
Ranked among companies with meaningful Days Payable only.
HSKA' s Days Payable Range Over the Past 10 Years
Min: 26.98  Med: 36.54 Max: 46.37
Current: 31.33
26.98
46.37

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
HSKA's 3-Year Dividend Growth Rate is ranked lower than
96% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.80 vs. HSKA: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
HSKA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
5-Year Yield-on-Cost % 0.90
HSKA's 5-Year Yield-on-Cost % is ranked lower than
70% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. HSKA: 0.90 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HSKA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.9
0.79
3.73
3-Year Average Share Buyback Ratio -7.30
HSKA's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. HSKA: -7.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSKA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.6  Med: -1.7 Max: -0.4
Current: -7.3
-38.6
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 155.77
HSKA's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. HSKA: 155.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HSKA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.37  Med: 3.86 Max: 207.5
Current: 155.77
2.37
207.5
Price-to-Tangible-Book 10.63
HSKA's Price-to-Tangible-Book is ranked lower than
74% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. HSKA: 10.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HSKA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.3  Med: 2.24 Max: 261.43
Current: 10.63
0.3
261.43
Price-to-Intrinsic-Value-Projected-FCF 9.11
HSKA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
90% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. HSKA: 9.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HSKA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.04 Max: 20.8
Current: 9.11
0.57
20.8
Price-to-Median-PS-Value 6.33
HSKA's Price-to-Median-PS-Value is ranked lower than
99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. HSKA: 6.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HSKA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.11 Max: 10.12
Current: 6.33
0.21
10.12
Price-to-Graham-Number 5.53
HSKA's Price-to-Graham-Number is ranked lower than
79% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. HSKA: 5.53 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HSKA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.2  Med: 2.2 Max: 44
Current: 5.53
0.2
44
Earnings Yield (Greenblatt) % 2.46
HSKA's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. HSKA: 2.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HSKA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 4 Max: 21.2
Current: 2.46
0.6
21.2
Forward Rate of Return (Yacktman) % -2.81
HSKA's Forward Rate of Return (Yacktman) % is ranked lower than
80% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. HSKA: -2.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HSKA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.3  Med: -2.1 Max: 7.5
Current: -2.81
-15.3
7.5

More Statistics

Revenue (TTM) (Mil) $120.3
EPS (TTM) $ 1.25
Beta0.45
Short Percentage of Float2.02%
52-Week Range $26.26 - 87.33
Shares Outstanding (Mil)6.90

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 126 144 161 173
EPS ($) 1.39 1.59 1.95 2.40
EPS without NRI ($) 1.39 1.59 1.95 2.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
30.10%
Dividends per Share ($)
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 

More From Other Websites
Heska Schedules Fourth Quarter and Year-End 2016 Financial Results Conference Call for February 28,... Jan 31 2017
Incyte Treats First Patient in Phase II GVHD Study on Jakafi Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017
HESKA CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 30 2016
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016
Corbus Concludes Phase II study of Cystic Fibrosis Candidate Dec 30 2016
Achillion Receives $15M from J&J for HCV Study Enrolment Dec 29 2016
Shire Gets FDA Approval for Label Expansion of Adynovate Dec 28 2016
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction Dec 28 2016
Neothetics (NEOT) Begins Phase II Study on Lead Candidate Dec 28 2016
Horizon's Rare Disease Drug Quinsair Launched in Canada Dec 27 2016
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug Dec 23 2016
Celgene's Otezla Gains Positive Recommendation from NICE Dec 23 2016
Roche (RHHBY) Hemophilia A Drug Positive in Phase III Dec 23 2016
Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo Dec 22 2016
Incyte/Merus Ink Collaboration for Bispecific Antibodies Dec 22 2016
Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU Dec 21 2016
Juno Gets Breakthrough Therapy Status for Lymphoma Drug Dec 21 2016
ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint Dec 21 2016
J&J Files for FDA Approval of Simponi Aria Label Expansion Dec 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)